Search Results - "GÖKMEN, Erhan"

Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series by ÖZKAN, Oğuzcan, GEÇGEL, Aslı, GÖKMEN, Erhan

“…The use of immune checkpoint inhibitors is increasing every day. With such frequent use, the side effects and management associated with these treatments are…”
Get full text

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey by Ünal, Çağlar, Özmen, Tolga, Ordu, Çetin, Pilanci, Kezban Nur, İlgün, Ahmet Serkan, Gökmen, Erhan, Almuradova, Elvina, Özdoğan, Mustafa, Güler, Nilüfer, Uras, Cihan, Kara, Halil, Demircan, Orhan, Işık, Selver, Alço, Gül, Saip, Pınar, Aydın, Esra, Duymaz, Tomris, Çelebi, Filiz, Yararbaş, Kanay, Soybir, Gursel, Ozmen, Vahit

“…The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive,…”
Get full text

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization by Ünal, Çağlar, Özmen, Tolga, Ordu, Çetin, Uras, Cihan, Kara, Halil, Gökmen, Erhan, Özdoğan, Mustafa, Demircan, Orhan, Pilancı, Kezban Nur, Duymaz, Tomris, Özmen, Vahit

“…ObjectiveThis study aimed to evaluate the relationship between PREDICT tool overall survival (OS) scores and high-risk patients according to TAILORx risk…”
Get full text

Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study by Özmen, Vahit, Çakar, Burcu, Gökmen, Erhan, Özdoğan, Mustafa, Güler, Nilufer, Uras, Cihan, Ok, Engin, Demircan, Orhan, Işıkdoğan, Abdurrahman, Saip, Pınar

“…Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict…”
Get full text

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey by Özmen, Vahit, Atasoy, Ajlan, Gökmen, Erhan, Özdoğan, Mustafa, Güler, Nilufer, Uras, Cihan, Ok, Engin, Demircan, Orhan, Işıkkdoğan, Abdurrahman, Cabioğlu, Neslihan, Şen, Fatma, Saip, Pınar

“…Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive…”
Get full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial by Cescon, David W, Nowecki, Zbigniew, Gallardo, Carlos, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Loi, Sherene, Guo, Zifang, Gonzalo, Gomez Abuin, Diego, Kaen, Matias, Molina, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Donatienne, Taylor, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Felipe, Silva, Joanne, Yu, Alejandro, Acevedo, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Jens-Uwe, Blohmer, Nadia, Harbeck, Jens, Huober, Christian, Kurbacher, Sibylle, Loibl, Tibor, Csoszi, Zsuzsanna, Kahan, Karoly, Mahr, John, Crown, Seamus, O'Reilly, Takaaki, Fujii, Hiroji, Iwata, Hirofumi, Mukai, Seigo, Nakamura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Masato, Takahashi, Koichiro, Tsugawa, Junichiro, Watanabe, Yutaka, Yamamoto, Teruo, Yamauchi, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Flavia, Morales-Vasquez, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Mei-Ching, Liu, Chiun-Sheng, Huang, Cagatay, Arslan, Irfan, Cicin, Erhan, Gokmen, Ozgur, Ozyilkan, Sinan, Yavuz, Janine, Graham, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Oleksii, Kolesnik, Olena, Kolesnik, Alla, Nasonova, Olga, Ponomarova, Dmytro, Trukhin, Sibel, Blau, Madhu, Chaudhry, Scott, Cole, William, Irvin, Randa, Loutfi, Janice, Lu, Coral, Omene, Timothy, Panella, Michael, Schleider, Robert, Siegel, Michael, Simon, Frances, Valdes-Albini

“…Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to…”
Get full text

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer by Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

“…Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than…”
Get full text

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Chan, Arlene, Prof, Delaloge, Suzette, MD, Holmes, Frankie A, MD, Moy, Beverly, MD, Iwata, Hiroji, MD, Harvey, Vernon J, MD, Robert, Nicholas J, MD, Silovski, Tajana, MD, Gokmen, Erhan, MD, von Minckwitz, Gunter, Prof, Ejlertsen, Bent, MD, Chia, Stephen K L, MD, Mansi, Janine, MD, Barrios, Carlos H, Prof, Gnant, Michael, Prof, Buyse, Marc, ScD, Gore, Ira, MD, Smith, John, MD, Harker, Graydon, MD, Masuda, Norikazu, MD, Petrakova, Katarina, MD, Zotano, Angel Guerrero, MD, Iannotti, Nicholas, MD, Rodriguez, Gladys, MD, Tassone, Pierfrancesco, Prof, Wong, Alvin, PharmD, Bryce, Richard, MBChB, Ye, Yining, PhD, Yao, Bin, MS, Martin, Miguel, Prof

“…Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive…”
Get full text

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG) by İçli, Fikri, Altundağ, Kadri, Akbulut, Hakan, Paydaş, Semra, Başaran, Gül, Saip, Pınar, Doğu, Gamze G., Eralp, Yeşim, Uslu, Rüçhan, Sevinç, Alper, Onur, Handan, Mandel, Nil M., Sezgin, Canfeza, Altınbaş, Mustafa, Güler, Nilüfer, Işıkdoğan, Abdurrahman, Gökmen, Erhan, Uygun, Kazım, Üstüner, Zeki, Yaren, Arzu, Demirkan, Binnaz, Coşkun, Uğur, Ata, Alper, Özkan, Metin, Arican, Ali

“…Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of…”
Get full text

Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis by Oytun, Merve Güner, Bulut, Gülcan, Gökmen, Erhan

“…Aim In recent years, the prognostic and predictive value of primary tumor localization in colon cancer has become increasingly important. This study aimed to…”
Get full text

Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer by Ece Solmaz, Aslı, Yeniay, Levent, Gökmen, Erhan, Zekioğlu, Osman, Haydaroğlu, Ayfer, Bilgen, Işıl, Özkınay, Ferda, Onay, Hüseyin

“…Breast cancer is the most common malignancy in women and thought to be hereditary in 10% of patients. Recent next-generation sequencing studies have increased…”
Get full text

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) by Lara, Jr, Primo N, Villanueva, Luis, Ibanez, Carolina, Erman, Mustafa, Lee, Jae Lyun, Heinrich, Daniel, Lipatov, Oleg Nikolaevich, Gedye, Craig, Gokmen, Erhan, Acevedo, Alejandro, Semenov, Andrey, Park, Se Hoon, Gafanov, Rustem Airatovich, Kose, Fatih, Jones, Mark, Du, Xiaoqi, Munteanu, Mihaela, Perini, Rodolfo, Choueiri, Toni K, Motzer, Robert J

“…Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor,…”
Get full text

Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre by Oytun, Merve Güner, Bulut, Gülcan, Gökmen, Erhan, Doğu, Burcu B, Karabulut, Bülent

“…Aim Decision- making of the treatment of colon cancer for the older patients becomes more complicated in consequence of comorbidities and geriatric syndromes,…”
Get full text

BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations by Solmaz, Aslı Ece, Onay, Hüseyin, Yeniay, Levent, Gökmen, Erhan, Özdemir, Necmettin, Alanyalı, Senem, Oktay, Ayşenur, Özsaran, Zeynep, Kapkaç, Murat, Özkınay, Ferda

“…•BRCA1/2 mutations detected nearly 10 percent of the patients who underwent testing.•Family history and age of diagnosis are the most important risk factors…”
Get full text

Long-Term Follow-Up of Patients with Male Breast Cancer, Single-Center Experience by Çakar, Burcu, Sert, Fatma, Gürsoy, Pınar, Emekdaş, Barış, Özsaran, Zeynep, Gökmen, Erhan, Haydaroğlu, Ayfer

“…OBJECTIVE Male breast cancer (BC) represents <1% of all BC cases. Our study aimed to define immunohistochemistry (IHC) based surrogate subtype distribution of…”
Get full text

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey by Ozmen, Vahit, Atasoy, Ajlan, Gokmen, Erhan, Ozdogan, Mustafa, Guler, Nilufer, Uras, Cihan, Ok, Engin, Demircan, Orhan, Isikdogan, Abdurrahman, Saip, Pinar

“…Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX(®) 21-gene assay is…”
Get full text

NVTG-07 SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC) AND ACTIVE BRAIN METASTASES (BMS) IN DESTINY-BREAST07 (DB-07) by Anders, Carey, Loi, Sherene, Hamilton, Erika, Jhaveri, Komal, Schmid, Peter, Gökmen, Erhan, Im, Seock-Ah, Karaçin, Cengiz, Barrios, Carlos, Park, Yeon Hee, Topaloğlu, Sernaz, Boston, Sarice, Konpa, Adam, Mondal, Shoubhik, André, Fabrice

“…Abstract BACKGROUND DEBBRAH, ROSET-BM, TUXEDO-1, and a pooled DB-01, -02, -03 analysis indicate robust efficacy of T-DXd in patients with stable/active BMs;…”
Get full text

Abstract P3-02-06: Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group by ERALP, Yeşim, DOĞAN, İzzet, Aksoy, Sercan, ÇAKAR, Burcu, BAŞARAN, Gül, ERCELEP, Özlem, MANDEL, Nil MOLİNAS, KORKMAZ, Taner, GÖKMEN, Erhan, AYDINER, Adnan, SAİP, Pınar

“…Abstract Background: Although HER2 is an aggressive subtype of BC, the outcomes have improved over the past two decades due to advances in targeted therapies…”
Get full text

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience by Bahçeci, Aykut, Paydaş, Semra, Ak, Naziye, Ferhatoğlu, Ferhat, Saip, Pınar Mualla, Seydaoğlu, Gülşah, Bilici, Mehmet, Şimşek, Melih, Tekin, Salim Başol, Çalikuşu, Züleyha, Yavuz, Sinan, Şahin, Ahmet Bilgehan, Çubukçu, Erdem, Evrensel, Türkkan, Değirmencioğlu, Serkan, Demiray, Atike Gökçen, Yumuk, Perran Fulden, Alan, Özkan, Çikman, Duygu İlke, Demirelli, Fuat Hulusi, Köstek, Osman, Gökyer, Ali, Doğan, Mutlu, Bal, Öznur, Çakar, Burcu, Gökmen, Erhan, Yamaç, Deniz, Korkmaz, Taner, Aliyev, Altay, Keskin, Özge, Urvay, Semiha, Büyükşimşek, Mahmut, Karadeniz, Cemile, Yildiz, Birol, Çinkir, Havva Yeşil, Demir, Hacer, Beypinar, İsmail, Karaçin, Cengiz, Eser, Kadir, Baykara, Meltem, Kiliçkap, Saadettin, Okutur, Kerem, Bulut, Gülcan, Alkan, Ali, Arpaci, Erkan, Pilanci, Kezban Nur, Demir, Atakan, Işik, Deniz, Yildirim, Nilgün

“…The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines…”
Get full text

Ege Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri by HAYDAROĞLU, Ayfer, ÇAKAR, Burcu, GÖKMEN, Erhan, ÖZDEMİR, Necmettin, ZEKİOĞLU, Osman, ÖZSARAN, Zeynep, ALANYALI, Senem, GÖKTEPE, Berk, YENİAY, Levent

“…Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 13079 meme kanser tanılı hastanın genel özellikleri, tedavi modaliteleri ve…”
Get full text